SARS-CoV-2 Reduction

Dr. Dana Yee M.D, Clinical Pathologist and Medical Director; Sam Kabbani, MS, BS, MT(ASCP), CLS, Chief Scientific Officer; Albert Brockman, Chief Biosafety Officer; Kevin Noble, Chief Operating Officer.
Innovative Bioanalysis, Inc.
Full Report


To evaluate the efficacy of the Defend 1050 / Pro XL at reducing SARS-CoV-2, the virus causing COVID-19.


The challenge pathogen, SARS-CoV-2 USA-CA1/2020, was used for testing the efficacy of the Defend 1050 / Pro XL. The bioaerosol efficacy challenge was completed in three distinct trials with the active pathogen to create a baseline of data. The Defend 1050 / Pro XL was placed in the same position for each viral challenge and operated in the same manner.

Two control tests were conducted without the Defend 1050 / Pro XL in the testing chamber. The control tests were used for the comparative baseline to assess the viral reduction when the Defend 1050 / Pro XL was operated in the challenge trials, to enable net reduction calculations to be made. The device was run at maximum speed (5).


The Defend 1050 / Pro XL achieved a 4.53 log10 reduction, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.


The Defend 1050 / Pro XL performed to manufacturer specifications and demonstrated a dramatic reduction of active virus after 30 minutes of exposure in aerosol form.

Every effort was made to simulate a real-life environment in the chamber while taking into consideration the special precautions needed when working with a Biosafety Level 3 Pathogen. Overall, the Defend 1050 / Pro XL device showed substantial efficacy in the removal of SARS-CoV-2 USA-CA1/2020 out of the breathable air.


Contact Us

USA Headquarters
290 Harbor Drive, 2nd Floor, Stamford, Connecticut 06902
Call: 1 866 508 1118  Email:

Ireland Headquarters
DCU Innovation Campus Old Finglas Road Glasnevin, Dublin 11
Call: +353 1 907 2750  Email: